Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shih-Shih Chen

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2013
Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signalingShih-Shih Chen, Franak Batliwalla, Nichol E Holodick, et al.
Blood|December 20, 2011
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoSabine Ponader, Shih-Shih Chen, Joseph J Buggy, et al.
Blood|October 23, 2024
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRDEkaterina Kim, Shih-Shih Chen, Mariela Sivina, et al.
Frontiers in Immunology|March 26, 2021
A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient MicePiers E M Patten, Gerardo Ferrer, Shih-Shih Chen, et al.
Leukemia|October 22, 2020
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemiaMariela Sivina, Lianchun Xiao, Ekaterina Kim, et al.
Blood|November 25, 2010
Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLLShih-Shih Chen, Rainer Claus, David M Lucas, et al.
Oncotarget|March 31, 2016
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cellsBurcu Yigit, Peter J Halibozek, Shih-Shih Chen, et al.
Leukemia|November 23, 2024
CLL crosstalk with naïve T cells enhances the differentiation of IL-22-producing T cells and CLL -cell survivalGerardo Ferrer, Florencia Palacios, Pui Yan Chiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse ModelCarsten U Niemann, Helena I Mora-Jensen, Eman L Dadashian, et al.
Cancer Research|May 3, 2008
Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemiaBjörn Hackanson, Kristi L Bennett, Romulo M Brena, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2013
Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signalingShih-Shih Chen, Franak Batliwalla, Nichol E Holodick, et al.
Blood|December 20, 2011
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoSabine Ponader, Shih-Shih Chen, Joseph J Buggy, et al.
Blood|October 23, 2024
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRDEkaterina Kim, Shih-Shih Chen, Mariela Sivina, et al.
Frontiers in Immunology|March 26, 2021
A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient MicePiers E M Patten, Gerardo Ferrer, Shih-Shih Chen, et al.
Leukemia|October 22, 2020
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemiaMariela Sivina, Lianchun Xiao, Ekaterina Kim, et al.
Blood|November 25, 2010
Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLLShih-Shih Chen, Rainer Claus, David M Lucas, et al.
Oncotarget|March 31, 2016
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cellsBurcu Yigit, Peter J Halibozek, Shih-Shih Chen, et al.
Leukemia|November 23, 2024
CLL crosstalk with naïve T cells enhances the differentiation of IL-22-producing T cells and CLL -cell survivalGerardo Ferrer, Florencia Palacios, Pui Yan Chiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse ModelCarsten U Niemann, Helena I Mora-Jensen, Eman L Dadashian, et al.
Cancer Research|May 3, 2008
Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemiaBjörn Hackanson, Kristi L Bennett, Romulo M Brena, et al.
Pageof 4